Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Ligia Mendes Soares, Jos Prickaerts, Humberto Milani, Elaine Del Bel, Harry Wilhelm Maria Steinbusch, Rubia Maria Weffort de Oliveira*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.
Original languageEnglish
Pages (from-to)1012-1023
JournalCns & Neurological Disorders-Drug Targets
Issue number8
Publication statusPublished - 2015


  • Animal models
  • brain ischemia
  • stroke
  • phosphodiesterase inhibitors

Cite this